IP Verse

Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure - EP3294283B1

PatentPatent Analysis

EP3294283

NOVARTIS
Application Number
EP16722388A
Filing Date
May 9, 2016
Status
Granted And Under Opposition
Feb 3, 2023
Grant Date
Mar 8, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Bibliography

The patent EP3294283B1 was granted to Novartis on Mar 8, 2023 following the initial filing on May 9, 2016 under the application number EP16722388A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (15)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BULLE DRDec 8, 2023ADMISSIBLE
KRKADec 8, 2023ADMISSIBLE
ZENTIVADec 8, 2023ADMISSIBLE
ALFRED E TIEFENBACHERDec 7, 2023ADMISSIBLE
BETAPHARM ARZNEIMITTELDec 7, 2023ADMISSIBLE
GENERICS UKDec 7, 2023ADMISSIBLE
POLPHARMADec 7, 2023ADMISSIBLE
SANOVEL IIAC SAN VE TICDec 7, 2023ADMISSIBLE
STRAWMANDec 7, 2023ADMISSIBLE
SYNTHONDec 7, 2023ADMISSIBLE
TEVA PHARMACEUTICALSDec 7, 2023ADMISSIBLE
HOFFMANN EITLEDec 4, 2023ADMISSIBLE
DR SCHONNov 30, 2023ADMISSIBLE
CAMULONNov 23, 2023ADMISSIBLE
EGISOct 9, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents